5 Best Small Cap Stocks To Buy for 2022

3. Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Number of Hedge Fund Holders: 23

Global Blood Therapeutics, Inc. (NASDAQ:GBT), a clinical-stage biopharmaceutical company, is a top small-cap stock to buy in 2022. The firm develops treatments to treat sickle-cell disease and other blood-based disorders. FDA recently approved Global Blood Therapeutics, Inc.’s (NASDAQ:GBT) Oxbryta tablet, an oral therapy to treat Sickle Cell Disease for children aged 4 to 11. In December, Stifel analyst Benjamin Burnett reiterated a Buy rating on Global Blood Therapeutics, Inc. (NASDAQ:GBT) shares, setting a $68 price target. The analyst sees Oxbryta’s approval in the US for pediatric use, as well as a probable European Union approval for adult use, delivering strong peak sales as sickle cell disease patients number roughly the same in the EU and the USA.

Perceptive Advisors is the leading shareholder of Global Blood Therapeutics, Inc. (NASDAQ:GBT) stock, with 4.4 million shares worth $112.3 million, as of the end of September. The hedge fund has increased its stake in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 7% over the previous quarter.

The gradual easing of headwinds caused by the Covid pandemic will afford further growth opportunities for the company, with its research and development pipeline also positioned to deliver value for investors. Investors were seen loading up on Global Blood Therapeutics, Inc. (NASDAQ:GBT) stock at the close of the third quarter, with 23 hedge funds bullish on the stock, as compared to 16 in the preceding quarter.